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Abstract: Short communication on Chronic Myelomonocytic Leukemia, with data on clinics, and the genes 
involved. 
 
Identity 
Chronic Myelomonocytic Leukemia (CMML) 
Note 
Chronic myelomonocytic leukemia (CMML) is the 
most frequent entity among myeloproliferative / 
myelodysplastic syndromes, as defined by the World 
Health Organization (WHO) classification of myeloid 
malignancies in 2008. The percentage of peripheral and 
marrow blast cells is the major prognostic factor 
identified at that time. Based on the percentage of blast 
cells in the bone marrow and peripheral blood, CMML 
is further stratified into CMML-1 (< 5% in blood, < 
10% in the bone marrow) and CMML-2 (5 - 19% in the 
blood; 10 to 19% in the bone marrow, or less if Auer 
inclusions are present). 
Clinics and pathology 
Disease 
Note 
The WHO criteria include 1) stable increase in 
peripheral blood monocyte count (> 1 x 109/L); 2) lack 
of Philadelphia chromosome and BCR-ABL fusion 
gene; 3) lack of gene rearrangement involving the 
Platelet-Derived Growth Factor Receptor Beta gene 
(PDGFRB); 4) blast cell percentage in the blood and 
the bone marrow lower than 20% and 5) cellular 
dysplasia of at least one myeloid cell line. This last 
criterion is not mandatory, as monocyte dysplasia can 
be difficult to assess in the bone marrow, and dysplasia 
of other lineages is inconstant. Thus, CMML may not 
always have a cytologically identifiable dysplastic 
component. When dysplasia is missing, diagnosis can 
be made if a clonal cytogenetic or molecular 
abnormality is identified in hematopoietic cells, or if 
peripheral blood monocyte count remains elevated at 
least 3 months without any other explanation. 
Phenotype/cell stem origin 
The cell of origin is a multipotential stem cell. 
Epidemiology 
CMML is a relatively rare disease whose incidence is 
around 1 case/100000 inhabitants per year. CMML is a 
disease of older adults, with a strong male 
predominance. The median age at diagnosis is around 
70 years, the disease is exceptionally diagnosed before 
50 years of age. 
Clinics 
The onset of the disease is usually insidious and, 
diagnosis is fortuitous in many cases. Symptoms, when 
present, are the consequences of cytopenias (notably 
anemia, which is invalidating in a third of patients), 
and/or of extramedullary hematopoiesis, notably 
splenomegaly but also hepatomegaly, skin infiltration, 
gum infiltration, and serous (notably pleural) effusions. 
Extramedullary hematopoiesis is mostly restricted to 
patients with WBC > 13 G/L. Finally, auto-immune 
manifestations (seronegative arthritis, vasculitis) can be 
associated to CMML. 
Cytology 
Peripheral blood count indicates monocytosis (up to 80 
x 109/L). Cells identified by cytologists as monocytes 
are heterogeneous, commonly including mature 
monocytes, dysplastic monocytes, and a variable 
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fraction of dysplastic granulocytes (these cells do not 
express CD14 but express granulocytic markers CD15 
and CD24, belong to the leukemic clone, and 
demonstrate immunosuppressive properties like 
myeloid-derived suppressive cells). An increase in 
neutrophils or eosinophils can be associated, as well as 
myelemia. Anemia is usually moderate, normocytic or 
macrocytic. Thrombocytopenia is inconstant and can be 
severe. Of note, an immune mechanism can contribute 
to these cytopenias. Hyperuricemia, increased B12 
plasma level, increase serum and urine lysozyme, and 
polyclonal hypergammaglobulinemia can be observed.  
Bone marrow: Bone marrow smears show a 
hypercellular tissue in which blast cell percentage 
(myeloblasts and monoblasts) remains lower than 20%. 
Monocyte proliferation is always present and often 
moderate (10 to 15% of mononuclear cells) and 
dysplastic changes can be observed in one or several 
lineages. A variable degree of myelofibrosis can be 
detected in up to 30% of patients. 
Treatment 
Allogeneic stem cell transplantation remains the only 
potentially curative option but is rarely feasible, due to 
the age of patients. In those ineligible for 
transplantation, the mainstay of CMML treatment is 
hydroxyurea, which is usually initiated when the 
disease becomes proliferative. The overall response 
rate reaches 60% but complete response is exceptional.  
The hypomethylating agent azacitidine (AZA) has been 
approved in Europe for CMML with WBC < 13 G/L 
and bone marrow blasts between 10 and 29%.  
The other hypomethylating agent, decitabine, is 
approved in US, not in Europe. An overall response 
rate of 40% is observed with these drugs. Prospective 
randomized comparisons of hypomethylating agents 
versus hydrxyurea have still to be performed. 
Prognosis 
The median survival for patients with CMML is 24-36 
months. According to the WHO, the main prognostic 
factor is the percentage of blast cells in the blood and 
the bone marrow. Several prognostic scores have been 
proposed that rely on peripheral blood counts, serum 
lactate deshydrogenase values, and percentage of bone 
marrow blast cells and cytogenetic abnormalities. More 
recent data suggest that cytogenetic and molecular 
information could be prognostically useful. 
Cytogenetics is part of a recent Spanish score whereas 
a recent French prognostic score includes the presence 
of mutations in ASXL1 gene, which is an independent 
poor prognostic factor in CMML. An international 
staging system may be established in the coming years. 
Cytogenetics 
Cytogenetics morphological 
Conventional metaphase karyotyping of bone marrow 
mononucleated cells is normal in two thirds of patients. 
By definition CMML cases do not show the 
Philadelphia chromosome.  
Cases associated with eosinophilia and rearrangements 
that fuse the platelet-derived growth factor receptor 
(PDGFRB) to another gene such as TEL in 
t(5;12)(q33;p13) are excluded from the CMML group 
by the WHO classification as this separate entity is 
sensitive to tyrosine kinase inhibitors such as Imatinib 
mesylate.  
The recurrent aberrations observed in CMML include 
loss of the Y chromosome, monosomy 7, trisomy 8, 
and interstitial deletions of chromosomes 20q, 11q, and 
12p, all of which may be seen in other myelodysplastic 
and myeloproliferative disorders.  
The proportion of patients showing large areas of 
uniparental disomy (UPD) in their blood cells, which is 
about 50% and could result from mitotic 
recombinations, is higher than in other myeloid 
malignancies. 
Genes involved and proteins 
Note 
Whole exome sequencing identifies a mean number of 
16 mutations in peripheral blood monocytes of patients 
with a CMML, none of which is specific of this entity. 
The recurrently mutated genes encode signaling 
molecules (NRAS, KRAS, CBL, JAK2, FLT3, CSF3R, 
NOTCH, NCSTN, MAML1), epigenetic regulators 
(TET2, ASXL1, EZH2, UTX, IDH1, IDH2, DNMT3A, 
SETBP1), splicing factors (SF3B1, SRSF2, ZRSF2, 
U2AF1), and cohesins (STAG1, STAG2, RAD21, 
SMC1A, SMC3, PDS5B).  
Mutations in the transcription regulators RUNX1, 
NPM1 and TP53 have also been reported in CMML. 
The most frequently mutated genes are TET2 (50-
60%), SRSF2 (40-50%), and ASXL1 (30-40%).  
TET2 and SRSF2 mutations are often combined. Most 
of the studies consistently report the poor prognosis of 
ASXL1 mutations. 
Aberrant gene expression profiles can be identified in 
the absence of gene mutation.  
In particular, expression of TIF1γ (transcription 
intermediary factor 1 gamma) is repressed by aberrant 
promoter hypermethylation in 35% of CMML patients, 
and conditional invalidation of TIF1γ leads to a 
CMML-like syndrome in aging mice. No direct link 
was identified between the repression of TIF1γ and 
other genes such as INK4B and the epigenetic gene 
mutations. 
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